Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CR011-vcMMAE · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| CR011-vcMMAE | DRUG | administered as an intravenous infusion on Day 1 of a 21 day cycle. |
Main Inclusion Criteria: * Females with confirmed breast cancer * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 * Locally advanced or metastatic disease who have received at least two prior chemotherapeutic regimens for breast cancer, as follows: * At least...
Top 20 of 92 competitors
CR011-vcMMAE is an investigational small molecule being studied for the treatment of unresectable Stage III or Stage IV melanoma and breast cancer. It is in Phase 1 clinical development and is not yet approved by the FDA.
CR011-vcMMAE is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker CLDX. The drug is currently in Phase 1 clinical trials for oncology indications.
CR011-vcMMAE is in Phase 1 clinical development. It has completed two Phase 1 trials, one in unresectable Stage III or Stage IV melanoma and one in breast cancer. The drug remains investigational and is not FDA approved.
CR011-vcMMAE has been studied in two completed Phase 1 trials. NCT00412828 enrolled 117 participants with unresectable Stage III or Stage IV melanoma in the United States. NCT00704158 enrolled 42 female participants with breast cancer in the United States.
CR011-vcMMAE is also known as glembatumumab vedotin. It is an antibody-drug conjugate targeting glycoprotein NMB, which is expressed in certain cancers. The drug is being developed by Celldex Therapeutics for melanoma and breast cancer.